Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines

Expert Review of Vaccines

Volumn 8, Issue 5, 2009, Pages 607-618

  Barrett, P Noel ^a   Mundt, Wolfgang ^a   Kistner, Otfried ^a   Howard, M Keith ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Continuous cell line; Emerging virus disease; Influenza; Rotavirus; Smallpox; Vero; Viral vaccine

Indexed keywords

CHIMERIVAX; CHIMERIVAX WNO2; DENGUE VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WEST NILE VACCINE;

AUTHORITY; BIOLOGICAL WARFARE; CARCINOGENICITY; CELL CULTURE; CELL LINE; CHIKUNGUNYA ALPHAVIRUS; CLINICAL TRIAL; DENGUE; DIPLOIDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EPIDEMIC ENCEPHALITIS; FLAVIVIRUS; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; ROSS RIVER ALPHA VIRUS; ROTAVIRUS; SCREENING; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE DRUG DOSE; SMALLPOX; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VERO CELL; VIRUS ENCEPHALITIS; VIRUS INFECTION; WEST NILE FLAVIVIRUS; ANIMAL; BIOSYNTHESIS; CERCOPITHECUS; CULTURE TECHNIQUE; DRUG APPROVAL; GENETICS; IMMUNOLOGY; RABIES VIRUS;

ANIMALS; CELL CULTURE TECHNIQUES; CERCOPITHECUS AETHIOPS; DRUG APPROVAL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; RABIES VIRUS; ROTAVIRUS; SMALLPOX; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES;

EID: 65649125562     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.19     Document Type: Review

References (95)

1. Enders J, Weller T, Robbins F. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109, 85-87 (1949).
2. Plotkin SL, Plotkin SA. A short history of vaccination. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 1-16 (2008).
3. Plotkin SA, Vidor E. Poliovirus vaccine - inactivated. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 605-629 (2008).
4. Dang-Tan T, Mahmud SM, Puntoni R, Franco EL. Polio vaccines, Simian v September irus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 23, 6535-6540 (2004). (Pubitemid 39265516)
5. Hayflick L, Moorehead PS. The serial cultivation of human diploid cell substrates. Exp. Cell. Res. 25, 585-621 (1961).
6. Plotkin SA. Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev. Infect. Dis. 2, 433-448 (1980).
7. US Department of Health, Education and Welfare, Public Health Service. Regulation for the Manufacture of Biological Products, title 42, part 73. DHEW pub. No. (NIH) 71-161, formerly PHS publ. No. 437, revised 1971-1976.
8. Cells, Products, Safety. Backgrounds papers from the WHO Study Group on Biologicals. Dev. Biol. Standard. 68, 1-90 (1987).
9. Yasumura Y, Kawakita Y. Study of SV40 in tissue culture. Nippon Rinsho. 21, 1201-1205 (1963).
10. Horaud F. Absence of viral sequences in the WHO-Vero cell bank a collaborative study. Dev. Biol. Standard. 76, 43-46 (1992).
11. Levenbook IS, Petricciano JC, Elisberg BL. Tumorigenicity of Vero cells. J. Biol. Stand. 12, 391-398 (1984). (Pubitemid 15119429)
12. Furesz J, Fanok A, Contreras G, Becker B. Tumorigenicity testing of various cell line substrates for production of biologicals. Dev. Biol. Stand. 70, 233-243 (1989).
13. Vincent-Falquet JC, Peyron L, Souvras M, Moulin JC, Tektoff J, Patet J. Qualification of working cell banks for the Vero cell line to produce licensed human vaccines. Dev. Biol. Stand. 70, 153-156 (1989).
14. Montagnon BJ, Vincent-Falquet JC, Saluzzo JF. Experience with Vero cells at Pasteur Mërieux Connaught. Dev. Biol. Stand. 98, 137-140 (1999).
15. WHO. Biological Substances No. 37. Requirements for continuous cell lines used for biologicals production. WHO technical report series, No. 745, 1987, Annex 3.
16. European Pharmacopoeia. Cell substrates for the production of vaccines for human use 2005: 50203 (2005).
17. US Department of Health and Human Services FDA. Guidance for industry: characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious disease (2006).
18. ICH Guidance Q5D: Derivation and characterization of cell substrates used for production of biotechnological/biological products. 63 FR 50244; 21 September, 1998.
19. Palache AM, Brands R, van Scharrenburg GJM. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176, 20-23 (1997). (Pubitemid 27315341)
20. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER-C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19, 2716-2721 (2001). (Pubitemid 32234294)
21. Montagnon BJ, Fanget B, Nicolas AJ. The large-scale cultivation of Vero cells in microcarrier culture for virus vaccine production: preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 47, 55-64 (1981). (Pubitemid 11186743)
22. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine - live. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 631-685 (2008).
23. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr. Infect. Dis. J. 16, 312-322 (1997). (Pubitemid 27131329)
24. Rhim JS, Schell K, Creasy B, Case W. Biological characteristics and viral susceptibility of an African green monkey kidney cell line (Vero). Proc. Soc. Exp. Biol. Med. 132, 670-678 (1969).
25. Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of Rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol. 2, 955-961 (1968).
26. Van Wezel AL, Van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev. Biol. Stand. 41, 159-168 (1978). (Pubitemid 9104700)
27. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16, 960-968 (1998). • Describes Vero technology and preclinical development of Vero-derived seasonal influenza vaccines. (Pubitemid 28276008)
28. Spruth M, Kistner O, Savidis-Dacho H et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralizing and protective antibody responses. Vaccine 24, 652-661 (2006). (Pubitemid 43017832)
29. Kistner O, Howard K, Spruth M et al. Cell culture (Vero) derived whole-virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25, 6028-6036 (2007). (Pubitemid 47077543)
30. Ehrlich HJ, Müller M, Oh HML et al. A cell culture (Vero) derived whole virus H5N1 vaccine is safe and induces antibody responses: results of a Phase I/II randomized controlled clinical trial. N. Engl. J. Med. 358, 2573-2584 (2008). •• Phase I/II clinical trial of Vero cell-derived H5N1 influenza vaccine. Strong neutralizing antibody titers were induced by low doses of nonadjuvanted vaccine.
31. Dennehy PH. Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 21, 198-208 (2008).
32. Clark HF, Offit PA, Plotkin SA, Heaton PM. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) - human rotavirus reassortants. Pediatr. Infect. Dis. J. 25, 577-583 (2006). (Pubitemid 43995352)
33. Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatr. Infect. Dis. J. 25, 42-47 (2006). • Phase III clinical trial with live pentavalent rotavirus vaccine in infants. The study demonstrated efficacy without adverse side effects. (Pubitemid 43884464)
34. Bernstein DI. Live attenuated human rotavirus vaccine, Rotarix. Semin. Pediatr. Infect. Dis. 17, 188-194 (2006).
35. O'Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev. Vaccines 6, 11-19 (2007).
36. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354, 11-22 (2006). • Phase III trial with monovalent rotavirus vaccine. Good cross-protection was induced against other serotypes, despite the vaccine being monovalent. (Pubitemid 43048947)
37. Kitano T, Oya A. Japanese encephalitis vaccine. In: Vaccine Handbook. Researcher's Associates TNIoH (Ed.). Maruzen, Tokyo 103-113 (1996).
38. Sugawara K, Nishiyama K, Ishikawa Y et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30, 303-314 (2002). (Pubitemid 36268966)
39. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, 98-109 (2004). (Pubitemid 40018233)
40. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines 7, 689-693 (2008).
41. Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet 370, 1847-1853 (2007). • Phase III study comparing Vero cell-derived Japanese encephalitis vaccine with licensed product. The Vero cell-derived vaccine safety profile and immunogenicity were superior to those of the mouse brain-derived licensed product. (Pubitemid 350186053)
42. Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis. 198, 493-499 (2008).
43. Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19, 4557-4565 (2001). (Pubitemid 32718682)
44. Lyons A, Kanesa-thasan N, Kuschner RA et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25, 3445-3453 (2007). (Pubitemid 46527985)
45. Torinawa H, Tomoyoshi K. Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium Vaccine 26, 3680-3689 (2008).
46. Kuzuhara S, Nakamura H, Hayashida K et al. Non-clinical and Phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21, 4519-4526 (2003). (Pubitemid 37315771)
47. Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257, 363-372 (1999). (Pubitemid 29393404)
48. Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213-1230 (2003). (Pubitemid 37338987)
49. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11, 480-496 (1998).
50. Edelman R. Dengue vaccines approach the finish line. Clin. Infect. Dis. 45, 56-60 (2007). • Provides a rationale and the specific issues relating to the development of dengue vaccines for use in adults and children. Insight is given into the differing approaches to development of a dengue vaccine. (Pubitemid 47036027)
51. Durbin AP, Karron RA, Sun W et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65, 405-413 (2001). (Pubitemid 33134570)
52. Blaney JE Jr, Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol. J. 4, 23 (2007). (Pubitemid 46393944)
53. Blaney JE Jr, Sathe NS, Goddard L et al. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4. Vaccine 26, 817-828 (2008).
54. Durbin AP, McArthur J, Marron JA et al. The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin. 2, 167-173 (2006). (Pubitemid 44422483)
55. Durbin AP, McArthur JH, Marron JA et al. rDEN2/4Δ30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2, 255-260 (2006). (Pubitemid 46025657)
56. Durbin AP, Whitehead SS, McArthur J et al. rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191, 710-718 (2005). (Pubitemid 40271058)
57. McArthur JH, Durbin AP, Marron JA et al. Phase I clinical evaluation of rDEN4Δ30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am. J. Trop. Med. Hyg. 79, 678-684 (2008).
58. Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis and Japanese encephalitis Adv. Virus Res. 61, 469-509 (2003). • Describes the use of molecular biology techniques to create novel, cost-effective live-attenuated flavivirus vaccines based on well-characterized nonrecombinant, attenuated vaccines, such as the 17D yellow fever vaccine. (Pubitemid 137640957)
59. Guirakhoo F, Pugachev K, Zhang Z et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78, 4761-4775 (2004). (Pubitemid 38501097)
60. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect. Dis. 2, 519-529 (2002). (Pubitemid 34966355)
61. Elizondo-Quiroga D, Davis CT, Fernandez-Salas I et al. West Nile virus isolation in human and mosquitoes, Mexico. Emerg. Infect. Dis. 11, 1449-1452 (2005). (Pubitemid 41209144)
62. Morales MA, Barrandeguy M, Fabbri C et al. West Nile virus isolation from equines in Argentina, 2006. Emerg. Infect. Dis. 12, 1559-1561 (2006). (Pubitemid 44570898)
63. Pepperell C, Rau N, Krajden S et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ 168, 1399-1405 (2003).
64. Monath TP, Liu J, Kanesa-thasan N et al. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci. USA 103, 6694-6699 (2006).
65. Arroyo J, Miller C, Catalan J et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 78, 12497-12507 (2004). (Pubitemid 39458768)
66. Lim CK, Takasaki T, Kotaki A, Kurane I. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 374, 60-70 (2008).
67. Pittman PR, Plotkin SA. Biodefense and special pathogen vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 1123-1133 (2008).
68. Murphy FA. Emerging zoonoses: the challenge for public health and biodefense. Prev. Vet. Med. 86, 216-223 (2008).
69. Peiris JS, Lai ST, Poon LL et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003). • Describes the clinical analysis of five linked clusters of severe acute respiratory syndrome (SARS) during the outbreak in Hong Kong, China. A coronavirus was isolated and characterized from two patients and evidence of infection with this virus was obtained in 45 out of 50 patients. (Pubitemid 36514862)
70. Communicable Diseases Surveillance. Commun. Dis. Intell. 20, 356-364 (1996).
71. Aaskov JG, Mataika JU, Lawrence GW et al. An epidemic of Ross River virus infection in Fiji, 1979. Am. J. Trop. Med. Hyg. 30, 1053-1059 (1981).
72. Kistner O, Barrett N, Brühmann A et al. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 25, 4845-4852 (2007). (Pubitemid 46818611)
73. Ravi V. Re-emergence of chikungunya virus in India. Indian J. Med. Microbiol. 24, 83-84 (2006). (Pubitemid 43747886)
74. Hochedez P, Jaureguiberry S, Debruyne M et al. Chikungunya infection in travelers. Emerg. Infect. Dis. 12, 1565-1567 (2006). (Pubitemid 44570900)
75. Dalla Pozza G, Majori G. First record of Aedes albopictus establishment in Italy. J. Am. Mosq. Control. Assoc. 8, 318-320 (1992).
76. Schuffenecker I, Iteman I, Michault A et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3, 1058-1070 (2006). (Pubitemid 44125992)
77. Wang E, Volkova E, Adams AP et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 26, 5030-5039 (2008).
78. Qu D, Zheng B, Yao X et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 23, 924-931 (2005). (Pubitemid 39643181)
79. Qin E, Shi H, Tang L et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 24, 1028-1034 (2006). (Pubitemid 43185321)
80. Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2), 31-44 (2004). • Describes in detail the rationale and development of an improved smallpox vaccine produced in Vero cell culture. (Pubitemid 39445966)
81. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 303, 706-709 (1983).
82. Robertson JS, Bootman JS, Newman R et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 160, 31-37 (1987). (Pubitemid 17138819)
83. Hardy CT, Young SA, Webster RG, Naeve CW, Owens RJ. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology 211, 302-306 (1995).
84. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM. The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J. Gen. Virol. 74, 2047-2051 (1993). (Pubitemid 23299881)
85. Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160, 191-198 (1989). • H3N2 virus grown in Madin-Darby canine kidney cells matched circulating wild-type virus better than egg-grown virus and provided superior protection in ferrets when compared with the egg-adapted variant from the same source. (Pubitemid 19189009)
86. Nakamura K, Homma M. Protein synthesis in Vero cells abortively infected with influenza B virus. J. Gen. Virol. 56, 199-202 (1981). (Pubitemid 12208664)
87. Lau SC, Scholtissek C. Abortive infection of Vero cells by an influenza A virus (FPV). Virology 212, 225-231 (1995).
88. Subbarao K, Chen H, Swayne D et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305, 192-200 (2003). (Pubitemid 36062823)
89. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23, 2943-2952 (2005). (Pubitemid 40386496)
90. WHO. Annex 5. WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines. WHO, Geneva, Switzerland (2005).
91. Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 389, 569-577 (2008).
92. Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Develop. Biol. Standard 70, 27-47 (1989).
93. Acambis www.acambis.co.uk (Accessed 16 October 2008)
94. Sinovac Biotech Ltd releases further results from SARS vaccine Phase I human clinical trial www.businesswire.com/portal/site/google/?ndmViewId=news- view&newsId=20041213005499&newsLang=en (Accessed 1 March 2009)
95. WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate vaccine viruses developed for potential use in human vaccines www.who.int/csr/disease/avian-influenza/guidelines/200902-H5VaccineVirusUpdate. pdf (Accessed 9 April 2009)